Paris, France

Carolina Martinez-Cingolani


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Immunotherapy: The Contributions of Carolina Martinez-Cingolani

Introduction

Carolina Martinez-Cingolani is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunotherapy, particularly in the development of antibodies targeting CD38, which is crucial in treating malignant hematological diseases such as multiple myeloma. Her innovative work has the potential to transform therapeutic approaches in oncology.

Latest Patents

Martinez-Cingolani holds a patent for "Antibodies having specificity for CD38 and uses thereof." This invention focuses on a new antibody against CD38, which is expressed in various malignant hematological diseases. The patent describes the development of Bi38-3, a bispecific T cell engager that targets CD38 on multiple myeloma cells. Bi38-3 effectively recruits cytotoxic T cells, triggering their proliferation and cytokine release, leading to the lysis of CD38 positive multiple myeloma cells in vitro. Importantly, Bi38-3 has shown efficacy in reducing tumor cells in a xenograft mouse model of human multiple myeloma, highlighting its potential as a novel immunotherapeutic tool.

Career Highlights

Throughout her career, Carolina has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de Paris. Her research has focused on the intersection of immunology and oncology, leading to groundbreaking advancements in cancer treatment.

Collaborations

Martinez-Cingolani has collaborated with notable colleagues, including Armand Bensussan and Jean-Christophe Bories. These partnerships have fostered a collaborative environment that enhances the development of innovative therapeutic strategies.

Conclusion

Carolina Martinez-Cingolani's work in developing targeted antibodies represents a significant advancement in the field of immunotherapy. Her contributions are paving the way for new treatment options for patients with malignant hematological diseases, particularly multiple myeloma.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…